DERL1 and central nervous system cancer: Moreover, HNF1β was a direct target of miR-217 and activated Derlin-1 via binding to its promoter via PI3K/AKT and ERK signaling pathways, suggesting blockage of circ-TTBK2/miR-217/HNF1β/Derlin-1 axis may be a potential therapeutic target for human gliomas [95–97].